
PRAX Stock Forecast & Price Target
PRAX Analyst Ratings
Bulls say
Praxis Precision Medicine's stock outlook appears positive due to significant advancements in the clinical efficacy of its product candidates, particularly vormatrigine, which demonstrated a 100% reduction in seizure frequency among patients, up from 56% in previous updates. The increased percentage of patients achieving 100% focal seizure reduction, now at over 33%, enhances its competitive position against existing treatments, suggesting potential for improved market share and persistence in usage. Furthermore, relutrigine's strong performance in demonstrating superior seizure reduction in specific genetic disorders indicates promising clinical data that could further bolster the company’s growth trajectory in the biopharmaceutical market.
Bears say
Praxis Precision Medicines Inc faces significant risks that may adversely impact its stock performance, including potential developmental failures in its key clinical-stage programs, vormatrigine and relutrigine, as well as the possibility of lower-than-expected sales from these candidates. Additionally, the company is susceptible to increased competitive pressure within the central nervous system disorder market, which could hinder its market share and profitability. Furthermore, reliance on third-party suppliers introduces manufacturing risks that could lead to delays in clinical trial timelines, compounding the overall uncertainty regarding the successful commercialization of its product candidates.
This aggregate rating is based on analysts' research of Praxis Precision Medicines and is not a guaranteed prediction by Public.com or investment advice.
PRAX Analyst Forecast & Price Prediction
Start investing in PRAX
Order type
Buy in
Order amount
Est. shares
0 shares